Arbutus Biopharma Statistics

Total Valuation

Arbutus Biopharma has a market cap or net worth of GBP 495.42 million. The enterprise value is 394.74 million.

Market Cap	495.42M
Enterprise Value	394.74M

Important Dates

The next estimated earnings date is Friday, February 28, 2025.

Earnings Date	Feb 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+10.83%
Shares Change (QoQ)	+0.51%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	136.22M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	6.21
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-6.90
EV / Sales	72.11
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.36

Financial Position

The company has a current ratio of 7.02, with a Debt / Equity ratio of 0.06.

Current Ratio	7.02
Quick Ratio	6.85
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	-0.09
Interest Coverage	-520.17

Financial Efficiency

Return on equity (ROE) is -67.81% and return on invested capital (ROIC) is -40.40%.

Return on Equity (ROE)	-67.81%
Return on Assets (ROA)	-32.83%
Return on Capital (ROIC)	-40.40%
Revenue Per Employee	68,907
Profits Per Employee	-783,916
Employee Count	73
Asset Turnover	0.05
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +39.64% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+39.64%
50-Day Moving Average	3.45
200-Day Moving Average	3.45
Relative Strength Index (RSI)	41.89
Average Volume (20 Days)	1,832

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.12

Income Statement

In the last 12 months, Arbutus Biopharma had revenue of GBP 5.03 million and -57.23 million in losses. Loss per share was -0.32.

Revenue	5.03M
Gross Profit	-41.82M
Operating Income	-58.60M
Pretax Income	-57.23M
Net Income	-57.23M
EBITDA	-57.55M
EBIT	-58.60M
Loss Per Share	-0.32

Full Income Statement

Balance Sheet

The company has 95.35 million in cash and 5.04 million in debt, giving a net cash position of 92.51 million.

Cash & Cash Equivalents	95.35M
Total Debt	5.04M
Net Cash	92.51M
Net Cash Per Share	n/a
Equity (Book Value)	79.75M
Book Value Per Share	0.42
Working Capital	84.95M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -53.59 million and capital expenditures -71,626, giving a free cash flow of -53.66 million.

Operating Cash Flow	-53.59M
Capital Expenditures	-71,626
Free Cash Flow	-53.66M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-1,165.03%
Pretax Margin	-1,137.64%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Arbutus Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.83%
Shareholder Yield	-10.83%
Earnings Yield	-11.55%
FCF Yield	-10.83%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Arbutus Biopharma has an Altman Z-Score of -4.92. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.92
Piotroski F-Score	n/a